سوق اعتلال الكلية IgA في الشرق الأوسط وأفريقيا، حسب نوع المرض (اعتلال الكلية IgA الأولي واعتلال الكلية IgA الثانوي)، الأعراض (البيلة الدموية، البول البروتيني، الوذمة وغيرها)، النوع (التشخيص والعلاج)، نوع السكان (الأطفال والبالغين)، طريق الإدارة (عن طريق الفم والحقن وغيرها)، المستخدم النهائي (المستشفيات والعيادات والرعاية الصحية المنزلية وغيرها)، قناة التوزيع (العطاء المباشر، صيدلية المستشفى، صيدلية التجزئة، الصيدلة عبر الإنترنت وغيرها)، الدولة (المملكة العربية السعودية وجنوب أفريقيا والإمارات العربية المتحدة وإسرائيل والكويت ومصر وبقية الشرق الأوسط وأفريقيا) اتجاهات الصناعة والتوقعات حتى عام 2028
تحليل السوق والرؤى: سوق اعتلال الكلية IgA في الشرق الأوسط وأفريقيا
من المتوقع أن يحقق سوق اعتلال الكلية IgA نموًا في السوق في الفترة المتوقعة من 2021 إلى 2028. تحلل شركة Data Bridge Market Research أن السوق ينمو بمعدل نمو سنوي مركب بنسبة 18.6٪ في الفترة المتوقعة من 2021 إلى 2028 ومن المتوقع أن يصل إلى 32.69 مليون دولار أمريكي بحلول عام 2028. تعد الاكتشافات الدوائية المتزايدة لاعتلال الكلية IgA هي المحركات الرئيسية التي تدفع الطلب على السوق في الفترة المتوقعة. يؤدي ارتفاع اضطراب اعتلال الكلية IgA إلى زيادة عبء المرض مما سيزيد من الطلب على منتجات التشخيص والعلاج، وبالتالي يعمل كمحرك لنمو سوق اعتلال الكلية IgA.
اعتلال الكلية IgA المعروف أيضًا باسم مرض بيرغر هو مرض يصيب الكلى وينتج عن تراكم رواسب IgA في الكلى مما يسبب الالتهاب وتلف أنسجة الكلى. الأجسام المضادة مثل IgA هي بروتينات ينتجها الجهاز المناعي لحماية الجسم من المواد الغريبة بما في ذلك البكتيريا والفيروسات. المضاعفات لهذا المرض هي ESKD والذي يتطلب بعد ذلك غسيل الكلى للعلاج.
تسمح زيادة خط أنابيب الأدوية المستهدفة لاعتلال الكلية IgA للمرشح المحتمل بإظهار فعالية علاج اعتلال الكلية IgA وبالتالي تعمل كمحرك لسوق اعتلال الكلية IgA. تزيد تكلفة علاج اعتلال الكلية IgA من العبء المالي للمريض في حالة عدم وجود تعويض وبالتالي تعمل كقيد لنمو سوق اعتلال الكلية IgA. يزيد تعاون اللاعبين في السوق لتطوير الأدوية من الحضور والابتكار في السوق وبالتالي يعمل كفرصة لنمو سوق اعتلال الكلية IgA. تعمل الآثار الجانبية المرتبطة بعلاج اعتلال الكلية IgA وتأثير COVID-19 على سوق الأدوية المثبطة للمناعة كتحدي لنمو سوق اعتلال الكلية IgA.
The IgA nephropathy market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the IgA nephropathy market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
IgA Nephropathy Market Scope and Market Size
The IgA nephropathy market is segmented on the basis of the disease type, symptoms, type, population type, route of administration, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of disease type, the IgA nephropathy market is segmented into primary IgA nephropathy and secondary IgA nephropathy. In 2021, primary IgA nephropathy segment is expected to dominate the market because the incidence of primary IgA nephropathy is more and can be diagnosed by blood or urine test easily.
- On the basis of symptoms, the IgA nephropathy market is segmented into hematuria, proteinuria, edema and others. In 2021, hematuria segment is expected to dominate the market as it is the most common and frequently used parameter for clinical examination and is detected by the amount of blood in the urine showing the occurrence of disease in the kidney.
- On the basis of type, the IgA nephropathy market is segmented into diagnosis and treatment. In 2021, the diagnosis segment is expected to dominate the market due to the fact that prior given the treatment, the proper detection and tracing of the IgA nephropathy is necessary which is possible only through the primary detection such as blood and urine test and confirmatory detection by kidney biopsy which are the major factor of this segment to dominate.
- On the basis of population type, the IgA nephropathy market is segmented into pediatrics and adults. In 2021, the adults segment is expected to show the significant growth because the studies showed the connection of this disease with ageing.
- On the basis of route of administration, the IgA nephropathy market is segmented into oral, parenteral and others. In 2021, the oral segment is expected to dominate the market due to the wide variety of oral product portfolio available in the interstate commerce by the market which increases the market of this segment.
- On the basis of end user, the IgA nephropathy market is segmented into hospitals, clinics, home healthcare and others. In 2021, hospitals segment is expected to dominate the market due to its strong financial structure.
- على أساس قناة التوزيع، يتم تقسيم سوق اعتلال الكلية IgA إلى العطاء المباشر، وصيدليات المستشفيات، وصيدليات التجزئة، والصيدليات عبر الإنترنت وغيرها. في عام 2021، يعمل قطاع العطاء المباشر على تسريع نمو الإيرادات بالإضافة إلى توفير مزايا ضريبية بسبب ازدهار قطاع العطاء المباشر خلال السنوات القليلة الماضية، ومن ثم، يوضح بشكل إيجابي المزيد من نمو السوق.
تحليل على مستوى الدولة لسوق اعتلال الكلية IgA في الشرق الأوسط وأفريقيا
يتم تحليل سوق اعتلال الكلية IgA في الشرق الأوسط وأفريقيا ويتم توفير معلومات حجم السوق حسب البلد ونوع المرض والأعراض والنوع ونوع السكان وطريقة الإدارة والمستخدم النهائي وقناة التوزيع كما هو مذكور أعلاه.
الدول التي يغطيها تقرير سوق اعتلال الكلية IgA في الشرق الأوسط وأفريقيا هي المملكة العربية السعودية وجنوب أفريقيا والإمارات العربية المتحدة وإسرائيل والكويت ومصر وبقية دول الشرق الأوسط وأفريقيا.
من المتوقع أن ينمو الشرق الأوسط وأفريقيا بأسرع معدل نمو سنوي مركب في فترة التوقعات، حيث يتزايد الطلب على اعتلال الكلية IgA في دول الشرق الأوسط وأفريقيا بسبب الطلب المتزايد على منتجات اعتلال الكلية IgA. ومن المتوقع أن تهيمن المملكة العربية السعودية على سوق اعتلال الكلية IgA في الشرق الأوسط وأفريقيا، حيث تعد المملكة العربية السعودية واحدة من الدول الرائدة في الشرق الأوسط وأفريقيا التي تستخدم منتجات وخدمات اعتلال الكلية IgA المتقدمة.
كما يقدم قسم الدولة في التقرير عوامل التأثير الفردية على السوق والتغييرات في التنظيم في السوق محليًا والتي تؤثر على الاتجاهات الحالية والمستقبلية للسوق. تعد نقاط البيانات مثل المبيعات الجديدة ومبيعات الاستبدال والتركيبة السكانية للدولة والقوانين التنظيمية ورسوم الاستيراد والتصدير من بين المؤشرات الرئيسية المستخدمة للتنبؤ بسيناريو السوق للدول الفردية. كما يتم النظر في وجود وتوافر العلامات التجارية في الشرق الأوسط وأفريقيا والتحديات التي تواجهها بسبب المنافسة الكبيرة أو النادرة من العلامات التجارية المحلية والمحلية وتأثير قنوات المبيعات أثناء تقديم تحليل توقعات لبيانات الدولة.
المبادرات الاستراتيجية من قبل الشركات المصنعة تخلق فرصًا جديدة للاعبين في سوق اعتلال الكلية IgA
يوفر لك سوق اعتلال الكلية IgA أيضًا تحليلًا تفصيليًا للسوق لكل نمو في كل دولة. علاوة على ذلك، يوفر بيانات تفصيلية بشأن النمو في مبيعات اعتلال الكلية IgA والشراكة والاستحواذ واتفاقية التوزيع بين اللاعبين في سوق اعتلال الكلية IgA في منطقة الشرق الأوسط وأفريقيا. البيانات متاحة للفترة التاريخية من 2011 إلى 2019.
تحليل المشهد التنافسي وحصة سوق اعتلال الكلية IgA
يوفر المشهد التنافسي لسوق اعتلال الكلية IgA تفاصيل حسب المنافس. تتضمن التفاصيل نظرة عامة على الشركة، والبيانات المالية للشركة، والإيرادات المتولدة، وإمكانات السوق، والاستثمار في البحث والتطوير، ومبادرات السوق الجديدة، ومواقع الإنتاج والمرافق، ونقاط القوة والضعف في الشركة، وإطلاق المنتج، وخطوط أنابيب تجارب المنتجات، وموافقات المنتج، وبراءات الاختراع، وعرض المنتج ونطاقه، وهيمنة التطبيق ومنحنى شريان الحياة التكنولوجي. ترتبط نقاط البيانات المذكورة أعلاه فقط بتركيز الشركة فيما يتعلق بسوق اعتلال الكلية IgA في الشرق الأوسط وأفريقيا.
اللاعبون الرئيسيون الذين تم تغطيتهم في تقرير سوق اعتلال الكلية IgA في الشرق الأوسط وأفريقيا هم AstraZeneca و Novartis AG و Pfizer Inc. و Zydus Cadila و Fresenius Kabi USA (شركة تابعة لشركة Fresenius SE & Co. KGaA) و Teva Pharmaceuticals USA، Inc. (شركة تابعة لشركة Teva Pharmaceutical Industries Ltd.) و Hikma Pharmaceuticals PLC و LUPIN و Siemens Healthcare GmBH (شركة تابعة لشركة Siemens Healthineers AG) و Sun Pharmaceutical Industries Ltd. و ARKRAY USA، Inc. و Merck Sharp & Dohme Corp.، وهي شركة تابعة لشركة Merck & Co.، Inc. و CareDX، Inc. و Alembic Pharmaceuticals Limited و Strides Pharma Science Limited و Apotex Inc. من بين اللاعبين المحليين الآخرين. يفهم محللو DBMR نقاط القوة التنافسية ويقدمون تحليلًا تنافسيًا لكل منافس على حدة.
كما يتم أيضًا إبرام العديد من العقود والاتفاقيات من قبل الشركات في جميع أنحاء العالم والتي تعمل أيضًا على تسريع سوق اعتلال الكلية IgA.
على سبيل المثال،
- في سبتمبر 2020، أعلنت شركة لوبين عن إطلاق أقراص أتورفاستاتين كالسيوم USP، المتوفرة بتركيزات 10 مجم/ 20 مجم/ 40 مجم و80 مجم، والتي تُستخدم لخفض نسبة الكوليسترول لدى البالغين والأطفال فوق سن 10 سنوات. وقد ساعد إطلاق المنتج الشركة في تحقيق المزيد من الإيرادات.
يعمل التعاون والمشاريع المشتركة والاستراتيجيات الأخرى من قبل اللاعبين في السوق على تعزيز انطباع الشركة في سوق اعتلال الكلية IgA والذي يوفر أيضًا فائدة للمنظمة لتحسين نمو مبيعات اعتلال الكلية IgA.
SKU-
احصل على إمكانية الوصول عبر الإنترنت إلى التقرير الخاص بأول سحابة استخبارات سوقية في العالم
- لوحة معلومات تحليل البيانات التفاعلية
- لوحة معلومات تحليل الشركة للفرص ذات إمكانات النمو العالية
- إمكانية وصول محلل الأبحاث للتخصيص والاستعلامات
- تحليل المنافسين باستخدام لوحة معلومات تفاعلية
- آخر الأخبار والتحديثات وتحليل الاتجاهات
- استغل قوة تحليل المعايير لتتبع المنافسين بشكل شامل
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 DISEASE TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET END USER COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES MODEL
4.3 CURRENT STUDIES ON ARCHAEOSOMES
5 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: COMPETITIVE ENVIRONMENT
6 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: REGULATIONS
6.1 THE U.S. REGULATORY FRAMEWORK FOR IGA NEPHROPATHY
6.2 EUROPE REGULATORY FRAMEWORK FOR IGA NEPHROPATHY
6.3 JAPAN REGULATORY FRAMEWORK FOR IGA NEPHROPATHY
7 EPIDEMIOLOGY
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 MIDDLE EAST AND AFRICA RISE IN IGA NEPHROPATHY DISORDER
8.1.2 1.1.2 INCREASING IGA TARGETED PIPELINE DRUGS
8.1.3 INCREASE RESEARCH & DEVELOPMENT INVESTMENT FOR DRUG DISCOVERY
8.1.4 REIMBURSEMENT PROVIDED FOR KIDNEY DISORDERS
8.1.5 1.1.5 UPCOMING AND RECENT APPROVAL FOR IGA NEPHROPATHY TREATMENT
8.2 RESTRAINTS
8.2.1 HIGH COST OF IGA NEPHROPATHY TREATMENT
8.2.2 DELAYED DIAGNOSIS OF IGA DISORDERS
8.2.3 POOR PLANNING OF IGA NEPHROPATHY TREATMENT IN LOW-INCOME COUNTRIES
8.2.4 INABILITY TO STOP PROGRESSION OF IGA NEPHROPATHY BY CURRENT TREATMENT
8.3 OPPORTUNITIES
8.3.1 COLLABORATION OF MARKET PLAYERS FOR DRUG DEVELOPMENT
8.3.2 GOVERNMENT FUNDING FOR RESEARCH PURPOSE
8.3.3 INCREASE TREND FOR NOVEL DIAGNOSIS PROCEDURE
8.4 CHALLENGES
8.4.1 LOW AWARENESS REGARDING KIDNEY DISEASE
8.4.2 SIDE EFFECT IGA NEPHROPATHY TREATMENT DRUGS
9 IMPACT OF COVID 19 ON THE MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET
9.1 IMPACT ON PRICE
9.2 IMPACT OF DEMAND:
9.3 IMPACT ON SUPPLY CHAIN:
9.4 STRATEGIC DECISIONS FOR MANUFACTURERS:
9.5 CONCLUSION:
10 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY DISEASE TYPE
10.1 OVERVIEW
10.2 PRIMARY IGA NEPHROPATHY
10.3 SECONDARY IGA NEPHROPATHY
11 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY SYMPTOMS
11.1 OVERVIEW
11.2 HEMATURIA
11.3 PROTEINURIA
11.4 EDEMA
11.5 OTHERS
12 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY TYPE
12.1 OVERVIEW
12.2 DIAGNOSIS
12.2.1 URINE TEST
12.2.1.1 URINE ALBUMIN-TO-CREATININE RATIO
12.2.1.2 DIPSTICK TEST FOR ALBUMIN AND BLOOD
12.2.2 BLOOD TEST
12.2.3 IOTHALAMATE CLEARANCE TEST
12.2.4 KIDNEY BIOPSY
12.2.5 OTHERS
12.3 TREATMENT
12.3.1 BLOOD PRESSURE LOWERING AGENTS
12.3.1.1 ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS
12.3.1.1.1 LISINOPRIL
12.3.1.1.2 ENALAPRIL
12.3.1.1.3 RAMIPRIL
12.3.1.1.4 BENAZEPRIL
12.3.1.1.5 OTHERS
12.3.1.2 ANGIOTENSIN RECEPTOR BLOCKERS (ARBS)
12.3.1.2.1 LOSARTAN
12.3.1.2.2 VALSARTAN
12.3.1.2.3 IRBESARTAN
12.3.1.2.4 OTHERS
12.3.2 IMMUNOSUPPRESANT
12.3.2.1 CYCLOPHOSPHAMIDE
12.3.2.2 AZATHIOPRINE
12.3.2.3 CORTICOSTEROIDS
12.3.2.3.1 METHYLPREDNISONE
12.3.2.3.2 PREDNISOLONE
12.3.2.3.3 OTHERS
12.3.2.4 OTHERS
12.3.3 DIURETICS
12.3.3.1 FUROSEMIDE
12.3.3.2 TORSEMIDE
12.3.3.3 BUMETANIDE
12.3.3.4 OTHERS
12.3.4 LOWER BLOOD CHOLESTEROL
12.3.4.1 ATROVASTATIN
12.3.4.2 SIMVASTATIN
12.3.4.3 ROSUVASTATIN
12.3.4.4 FLUVASTATIN
12.3.4.5 PRAVASTATIN
12.3.4.6 OTHERS
12.3.5 SUPPLEMENTS
12.3.5.1 OMEGA-3-FATTY ACIDS
12.3.5.2 VITAMIN E
12.3.5.3 OTHERS
12.3.6 OTHERS
13 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY POPULATION TYPE
13.1 OVERVIEW
13.2 ADULTS
13.3 CHILDREN
14 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION
14.1 OVERVIEW
14.2 ORAL
14.2.1 TABLETS/PILLS
14.2.2 CAPSULES
14.2.3 OTHERS
14.3 PARENTERAL
14.3.1 INTRAVENOUS
14.3.2 INTRAMUSCULAR
14.3.3 OTHERS
14.4 OTHERS
15 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 CLINICS
15.4 HOME HEALTHCARE
15.5 OTHERS
16 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 HOSPITAL PHARMACY
16.3 RETAIL PHARMACY
16.4 ONLINE PHARMACY
16.5 DIRECT TENDER
16.6 OTHERS
17 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET BY GEOGRAPHY
17.1 MIDDLE EAST & AFRICA
17.1.1 SAUDI ARABIA
17.1.2 SOUTH AFRICA
17.1.3 ISRAEL
17.1.4 ISRAEL
17.1.5 KUWAIT
17.1.6 EGYPT
17.1.7 REST OF MIDDLE EAST & AFRICA
18 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
19 SWOT
20 COMPANY PROFILES
20.1 VIATRIS INC.
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENTS
20.2 TEVA PHARMACEUTICAL USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE FINANCIALS
20.2.3 COMPANY SHARE ANALYSIS
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENTS
20.3 LUPIN
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE FINANCIALS
20.3.3 COMPANY SHARE ANALYSIS
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENTS
20.4 ACCORD HEALTHCARE
20.4.1 COMPANY SNAPSHOT
20.4.2 COMPANY SHARE ANALYSIS
20.4.3 PRODUCT PORTFOLIO
20.4.4 RECENT DEVELOPMENTS
20.5 ASTRAZENECA
20.5.1 COMPANY SNAPSHOT
20.5.2 RECENT FINANCIALS
20.5.3 PRODUCT PORTFOLIO
20.5.4 RECENT DEVELOPMENTS
20.6 PFIZER INC.
20.6.1 COMPANY SNAPSHOT
20.6.2 REVENUE FINANCIALS
20.6.3 PRODUCT PORTFOLIO
20.6.4 RECENT DEVELOPMENTS
20.7 ZYDUS CADILLA
20.7.1 COMPANY SNAPSHOT
20.7.2 REVENUE FINANCIALS
20.7.3 PRODUCT PORTFOLIO
20.7.4 RECENT DEVELOPMENTS
20.8 NOVARTIS AG
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE FINANCIALS
20.8.3 PRODUCT PORTFOLIO
20.8.4 RECENT DEVELOPMENTS
20.9 ALEMBIC PHARMACEUTICALS LIMITED
20.9.1 COMPANY SNAPSHOT
20.9.2 REVENUE ANALYSIS
20.9.3 PRODUCT PORTFOLIO
20.9.4 RECENT DEVELOPMENTS
20.1 STRIDES PHARMA SCIENCE LIMITED
20.10.1 COMPANY SNAPSHOT
20.10.2 REVENUE FINANCIALS
20.10.3 PRODUCT PORTFOLIO
20.10.4 RECENT DEVELOPMENTS
20.11 SIEMENS HEALTHCARE GMBH (A SUBSIDIARY OF SIEMENS HEALTHINEERS AG)
20.11.1 COMPANY SNAPSHOT
20.11.2 REVENUE FINANCIALS
20.11.3 PRODUCT PORTFOLIO
20.11.4 RECENT DEVELOPMENTS
20.12 MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.
20.12.1 COMPANY SNAPSHOT
20.12.2 REVENUE ANALYSIS
20.12.3 PRODUCT PORTFOLIO
20.12.4 RECENT DEVELOPMENTS
20.13 HIKMA PHARMACEUTICALS PLC
20.13.1 COMPANY SNAPSHOT
20.13.2 REVENUE ANALYSIS
20.13.3 PRODUCT PORTFOLIO
20.13.4 RECENT DEVELOPMENTS
20.14 SUN PHARMACEUTICAL INDUSTRIES LTD.
20.14.1 COMPANY SNAPSHOT
20.14.2 REVENUE FINANCIALS
20.14.3 PRODUCT PORTFOLIO
20.14.4 RECENT DEVELOPMENT
20.15 APOTEX INC.
20.15.1 COMPANY SNAPSHOT
20.15.2 PRODUCT PORTFOLIO
20.15.3 RECENT DEVELOPMENTS
20.16 ARKRAY USA, INC.
20.16.1 COMPANY SNAPSHOT
20.16.2 PRODUCT PORTFOLIO
20.16.3 RECENT DEVELOPMENTS
20.17 CALIDITAS THERAPEUTICS AB
20.17.1 COMPANY SNAPSHOT
20.17.2 REVENUE FINANCIALS
20.17.3 PRODUCT PORTFOLIO
20.17.4 RECENT DEVELOPMENTS
20.18 CAREDX, INC.
20.18.1 COMPANY SNAPSHOT
20.18.2 REVENUE ANALYSIS
20.18.3 PRODUCT PORTFOLIO
20.18.4 RECENT DEVELOPMENTS
20.19 FRESENIUS KABI USA (A SUBSIDIARY OF FRESENIUS SE & CO. KGAA)
20.19.1 COMPANY SNAPSHOT
20.19.2 REVENUE FINANCIALS
20.19.3 PRODUCT PORTFOLIO
20.19.4 RECENT DEVELOPMENTS
20.2 OMEROS CORPORATION
20.20.1 COMPANY SNAPSHOT
20.20.2 REVENUE ANALYSIS
20.20.3 PRODUCT PORTFOLIO
20.20.4 RECENT DEVELOPMENTS
21 QUESTIONNAIRE
22 RELATED REPORTS
List of Table
TABLE 1 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 2 MIDDLE EAST AND AFRICA PRIMARY IGA NEPHROPATHY IN IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 3 MIDDLE EAST AND AFRICA SECONDARY IGA NEPHROPATHY IN IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA HEMATURIA IN IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA PROTEINURIA IN IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA EDEMA IN IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA OTHERS IN IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA URINE TEST IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA TREATMENT BY IMMUNOSUPPRESSANT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA TREATMENT BY DIURETICS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA TREATMENT BY DIURETICS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA ADUTLS IN IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA CHILDREN IN IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA PARENTERAL IN IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA OTHERS IN IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA HOSPITALS IN IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 SPECIALTY CLINICS IN IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA HOME HEALTHCARE IN IGA NEPHROPATHY MARKET, BY REGION, 20190-2028 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA OTHERS IN IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA HOPSITAL PHARMACY IN IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA RETAIL PHARMACY IN IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA ONLINE PARMACY IN IGA NEPHROPATHY MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA DIRECT TENDER IN IGA NEPHROPATHY MARKET, BY REGION, 2018-2028 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA OTHERS IN IGA NEPHROPATHY MARKET, BY REGION, 2018-2028 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 45 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 46 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 47 MIDDLE EAST & AFRICA DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 48 MIDDLE EAST & AFRICA DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 50 MIDDLE EAST & AFRICA TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 52 MIDDLE EAST & AFRICA TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 53 MIDDLE EAST & AFRICA TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 54 MIDDLE EAST & AFRICA TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 55 MIDDLE EAST & AFRICA TREATMENT BY DIURETICS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 57 MIDDLE EAST & AFRICA TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 58 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 59 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 60 MIDDLE EAST & AFRICA ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 61 MIDDLE EAST & AFRICA PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 62 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 63 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 64 SAUDI ARABIA IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 65 SAUDI ARABIA IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 66 SAUDI ARABIA IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 67 SAUDI ARABIA DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 68 SAUDI ARABIA DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 69 SAUDI ARABIA TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 70 SAUDI ARABIA TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 71 SAUDI ARABIA TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 72 SAUDI ARABIA TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 73 SAUDI ARABIA TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 74 SAUDI ARABIA TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 75 SAUDI ARABIA IGA TREATMENT BY DIURETICS IN NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 76 SAUDI ARABIA TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 77 SAUDI ARABIA TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 78 SAUDI ARABIA IGA NEPHROPATHY MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 79 SAUDI ARABIA IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 80 SAUDI ARABIA ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 81 SAUDI ARABIA PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 82 SAUDI ARABIA IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 83 SAUDI ARABIA IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 84 SOUTH AFRICA IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 85 SOUTH AFRICA IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 86 SOUTH AFRICA IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 87 SOUTH AFRICA DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 88 SOUTH AFRICA DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 89 SOUTH AFRICA TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 90 SOUTH AFRICA TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 91 SOUTH AFRICA TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 92 SOUTH AFRICA TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 93 SOUTH AFRICA TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 94 SOUTH AFRICA TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 95 SOUTH AFRICA TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 96 SOUTH AFRICA TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 97 SOUTH AFRICA TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 98 SOUTH AFRICA IGA NEPHROPATHY MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 99 SOUTH AFRICA IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 100 SOUTH AFRICA ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 101 SOUTH AFRICA PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 102 SOUTH AFRICA IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 103 SOUTH AFRICA IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 104 ISRAEL IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 105 ISRAEL IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 106 ISRAEL IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 107 ISRAEL DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 108 ISRAEL DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 109 ISRAEL TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 110 ISRAEL TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 111 ISRAEL TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 112 ISRAEL TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 113 ISRAEL TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 114 ISRAEL TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 115 ISRAEL TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 116 ISRAEL TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 117 ISRAEL TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 118 ISRAEL IGA NEPHROPATHY MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 119 ISRAEL IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 120 ISRAEL ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 121 ISRAEL PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 122 ISRAEL IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 123 ISRAEL IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 124 ISRAEL IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 125 ISRAEL IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 126 ISRAEL IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 127 ISRAEL DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 128 ISRAELDIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 129 ISRAEL TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 130 ISRAEL TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 131 ISRAEL TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 132 ISRAEL TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 133 ISRAEL TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 134 ISRAEL TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 135 ISRAEL TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 136 ISRAEL TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 137 ISRAEL TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 138 ISRAEL IGA NEPHROPATHY MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 139 ISRAEL IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 140 ISRAEL ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 141 ISRAEL PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 142 ISRAEL IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 143 ISRAEL IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 144 KUWAIT IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 145 KUWAIT IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 146 KUWAIT IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 147 KUWAIT DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 148 KUWAITDIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 149 KUWAIT TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 150 KUWAIT TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 151 KUWAIT TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 152 KUWAIT TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 153 KUWAIT TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 154 KUWAIT TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 155 KUWAIT TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 156 KUWAIT TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 157 KUWAIT TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 158 KUWAIT IGA NEPHROPATHY MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 159 KUWAIT IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 160 KUWAIT ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 161 KUWAIT PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 162 KUWAIT IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 163 KUWAIT IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 164 EGYPT IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 165 EGYPT IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 166 EGYPT IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 167 EGYPT DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 168 EGYPTDIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 169 EGYPT TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 170 EGYPT TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 171 EGYPT TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 172 EGYPT TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 173 EGYPT TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 174 EGYPT TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 175 EGYPT TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 176 EGYPT TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 177 EGYPT TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 178 EGYPT IGA NEPHROPATHY MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 179 EGYPT IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 180 EGYPT ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 181 EGYPT PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 182 EGYPT IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 183 EGYPT IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 184 REST OF MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
List of Figure
FIGURE 1 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: MULTIVARIATE MODELLING
FIGURE 7 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: MARKET END USER COVERAGE GRID
FIGURE 11 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: SEGMENTATION
FIGURE 12 MIDDLE EAST AND AFRICA RISE IN IGA NEPHROPATHY DISORDER IS DRIVING THE MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 PRIMARY IGA NEPHROPATHY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET
FIGURE 15 IGA NEPHROPATHY BIOPSIES IN DIFFERENT REGIONS
FIGURE 16 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY DISEASE TYPE, 2020
FIGURE 17 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY DISEASE TYPE, 2020-2028 (USD MILLION)
FIGURE 18 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY DISEASE TYPE, CAGR (2020-2028)
FIGURE 19 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 20 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY SYMPTOMS, 2020
FIGURE 21 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY SYMPTOMS, 2020-2028 (USD MILLION)
FIGURE 22 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY SYMPTOMS, CAGR (2020-2028)
FIGURE 23 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY SYMPTOMS, LIFELINE CURVE
FIGURE 24 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY TYPE, 2020
FIGURE 25 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY TYPE, 2020-2028 (USD MILLION)
FIGURE 26 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY TYPE, CAGR (2020-2028)
FIGURE 27 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY TYPE, LIFELINE CURVE
FIGURE 28 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY POPULATION TYPE, 2020
FIGURE 29 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY POPULATION TYPE, 2020-2028 (USD MILLION)
FIGURE 30 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY POPULATION TYPE, CAGR (2020-2028)
FIGURE 31 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 32 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 33 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY ROUTE OFADMINISTRATION, 2020-2028 (USD MILLION)
FIGURE 34 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2028)
FIGURE 35 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 36 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY END USER, 2020
FIGURE 37 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY END USER , 2020-2028 (USD MILLION)
FIGURE 38 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY END USER, CAGR (2020-2028)
FIGURE 39 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 41 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 42 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028)
FIGURE 43 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET: SNAPSHOT (2020)
FIGURE 45 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET: BY COUNTRY (2020)
FIGURE 46 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET: BY COUNTRY (2021 & 2028)
FIGURE 47 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET: BY COUNTRY (2020 & 2028)
FIGURE 48 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET: BY DISEASE TYPE (2021-2028)
FIGURE 49 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: COMPANY SHARE 2020 (%)
منهجية البحث
يتم جمع البيانات وتحليل سنة الأساس باستخدام وحدات جمع البيانات ذات أحجام العينات الكبيرة. تتضمن المرحلة الحصول على معلومات السوق أو البيانات ذات الصلة من خلال مصادر واستراتيجيات مختلفة. تتضمن فحص وتخطيط جميع البيانات المكتسبة من الماضي مسبقًا. كما تتضمن فحص التناقضات في المعلومات التي شوهدت عبر مصادر المعلومات المختلفة. يتم تحليل بيانات السوق وتقديرها باستخدام نماذج إحصائية ومتماسكة للسوق. كما أن تحليل حصة السوق وتحليل الاتجاهات الرئيسية هي عوامل النجاح الرئيسية في تقرير السوق. لمعرفة المزيد، يرجى طلب مكالمة محلل أو إرسال استفسارك.
منهجية البحث الرئيسية التي يستخدمها فريق بحث DBMR هي التثليث البيانات والتي تتضمن استخراج البيانات وتحليل تأثير متغيرات البيانات على السوق والتحقق الأولي (من قبل خبراء الصناعة). تتضمن نماذج البيانات شبكة تحديد موقف البائعين، وتحليل خط زمني للسوق، ونظرة عامة على السوق ودليل، وشبكة تحديد موقف الشركة، وتحليل براءات الاختراع، وتحليل التسعير، وتحليل حصة الشركة في السوق، ومعايير القياس، وتحليل حصة البائعين على المستوى العالمي مقابل الإقليمي. لمعرفة المزيد عن منهجية البحث، أرسل استفسارًا للتحدث إلى خبراء الصناعة لدينا.
التخصيص متاح
تعد Data Bridge Market Research رائدة في مجال البحوث التكوينية المتقدمة. ونحن نفخر بخدمة عملائنا الحاليين والجدد بالبيانات والتحليلات التي تتطابق مع هدفهم. ويمكن تخصيص التقرير ليشمل تحليل اتجاه الأسعار للعلامات التجارية المستهدفة وفهم السوق في بلدان إضافية (اطلب قائمة البلدان)، وبيانات نتائج التجارب السريرية، ومراجعة الأدبيات، وتحليل السوق المجدد وقاعدة المنتج. ويمكن تحليل تحليل السوق للمنافسين المستهدفين من التحليل القائم على التكنولوجيا إلى استراتيجيات محفظة السوق. ويمكننا إضافة عدد كبير من المنافسين الذين تحتاج إلى بيانات عنهم بالتنسيق وأسلوب البيانات الذي تبحث عنه. ويمكن لفريق المحللين لدينا أيضًا تزويدك بالبيانات في ملفات Excel الخام أو جداول البيانات المحورية (كتاب الحقائق) أو مساعدتك في إنشاء عروض تقديمية من مجموعات البيانات المتوفرة في التقرير.
